# Telix Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/telix-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Melbourne, Australia
- Website: www.telixpharma.com
- Total disclosed funding: $8.5M
- Latest round: Seed (Jun 1, 2016)
- Investors on record: 5

## About

Based in Victoria, Australia, Telix Pharmaceuticals Limited specializes in developing and commercializing theranostic radiopharmaceuticals to meet significant unmet medical needs in oncology.Telix Pharmaceuticals Limited, founded in 2015 in Melbourne, Australia, is focused on the development of innovative radiopharmaceuticals for oncology. The company has undergone strategic pivots to enhance its product pipeline and funding capabilities. The firm recently completed an IPO in November 2017, raising AUD 50 million. The CEO, David Cade, has a history of leadership in biopharmaceutical companies, providing a foundation for Telix's growth. The company operates globally, with key locations in North America and Australia.Telix Pharmaceuticals focuses on the development and commercialization of theranostic radiopharmaceuticals, combining therapeutic and diagnostic functions to address significant unmet medical needs in oncology. The company's primary products include Illuccix®, an imaging agent approved by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) for detecting prostate cancer, and Gozellix®, another product currently under development. These agents utilize targeted radiation to enhance treatment decision-making and deliver personalized therapies, particularly in areas of urologic oncology, neuro-oncology, musculoskeletal oncology, and bone marrow conditioning. Telix’s products are primarily marketed in North America, including the United States and Canada, as well as other global markets where regulatory approvals have been attained. The company's client base consists of healthcare institutions, clinics, and hospitals that aim to improve patient care through advanced imaging and treatment options.Telix Pharmaceuticals reports significant revenues from its product offerings, primarily generated through direct sales to healthcare providers and institutions utilizing the company's imaging agents in clinical settings. Transactions typically occur via contracts with hospitals and clinics, where products such as Illuccix® are purchased for use in diagnostic imaging processes. The firm operates on a business-to-business (B2B) model, focusing on institutional partnerships that facilitate the distribution of its products. The specifics of the pricing structure contribute directly to the company's revenue stream; however, detailed pricing information is not disclosed.Telix Pharmaceuticals plans to utilize the proceeds from its AUD 50 million IPO in November 2017 to fund the development and completion of clinical trials for its pipeline in renal, prostate, and brain cancer (glioblastoma), as well as to complete multiple clinical and product development milestones over the next 24 months. The company aims to launch new products in its pipeline and expand into additional markets, specifically targeting regions in Europe and Asia by 2024. These initiatives are expected to enhance the company's offerings and strengthen its market presence.

## Funding rounds

- Seed, Jun 1, 2016, $8.5M — Viburnum Funds, CVC, Monash Investors, Acorn Capital, Allan Moss Investments

## Investors

- Viburnum Funds (https://capitalatlas.ai/funds/viburnum-funds) — Seed
- CVC (https://capitalatlas.ai/funds/cvc) — Seed
- Monash Investors — Seed
- Acorn Capital — Seed
- Allan Moss Investments — Seed